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Tregs play a fundamental role in immune tolerance via control of self-reactive effector T
cells (Teffs). This function is dependent on maintenance of a high intracellular cAMP
concentration. A number of microRNAs are implicated in the maintenance of Tregs. In this
study, we demonstrate that peripheral immune tolerance is critically dependent on
posttranscriptional repression of the cAMP-hydrolyzing enzyme phosphodiesterase-3b
(Pde3b) by microRNA-142-5p (miR-142-5p). In this manner, miR-142-5p acts as an
immunometabolic regulator of intracellular cAMP, controlling Treg suppressive function.
Mir142 was associated with a super enhancer bound by the Treg lineage–determining
transcription factor forkhead box P3 (FOXP3), and Treg-specific deletion of miR-142 in mice
(TregΔ142) resulted in spontaneous, lethal, multisystem autoimmunity, despite preserved
numbers of phenotypically normal Tregs. Pharmacological inhibition and genetic ablation of
PDE3B prevented autoimmune disease and reversed the impaired suppressive function of
Tregs in TregΔ142 animals. These findings reveal a critical molecular switch, specifying
Treg function through the modulation of a highly conserved, cell-intrinsic metabolic
pathway. Modulation of this pathway has direct relevance to the pathogenesis and treatment
of autoimmunity and cancer.
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Introduction
miRNAs are a class of small (~21–25 nucleotides), highly conserved, 
endogenous noncoding RNAs that regulate gene expression post-
transcriptionally. This function is mediated through binding of the 
miRNA-containing RNA-induced silencing complex (miRISC) to 
complementary sequences in the 3′ UTR of target mRNAs, ulti-
mately causing mRNA degradation or translational inhibition (1, 
2). Through these regulatory actions, miRNAs have been shown to 
be critical for normal innate and adaptive immune processes (3), 
with aberrant expression implicated in multiple autoimmune dis-
eases and malignancies (4, 5). Potential susceptibility to pharma-
cological manipulation with modified antisense oligonucleotides 
also makes them attractive therapeutic targets (6).
Tregs are primarily CD4 positive and play an essential role in 
maintenance of peripheral tolerance and avoidance of autoimmu-
nity through the direct suppression of self-reactive effector T cells 
(Teffs). The Treg lineage is defined by expression of the transcrip-
tion factor forkhead box P3 (FOXP3, also known as Scurfin), whose 
gene locus is located on the X chromosome (7). FOXP3 is exclusive-
ly expressed by Tregs and is critical for Treg lineage commitment. 
The importance of Tregs for maintenance of peripheral tolerance 
was highlighted by studies of the Scurfy mouse, which lacks func-
tional Tregs due to a missense mutation in the murine Foxp3 gene. 
These mice develop a severe lymphoproliferative disease with gen-
eralized multiorgan inflammation, leading to death by 24 days of 
age (8, 9). A similar outcome is observed in human patients suffer-
ing from immunodysregulation, polyendocrinopathy, enteropathy, 
X-linked (IPEX) syndrome. IPEX syndrome is also caused by muta-
tions in the FOXP3 gene and is characterized by defective Tregs, 
multisystem inflammation, and autoimmunity, with death usually 
by 2 years of age unless successfully treated (10, 11). Importantly, 
mice with a Treg-specific deletion of either Dicer (12–14) or Drosha 
(15), the 2 ribonuclease III (RNase III) enzymes necessary for the 
production and processing of mature miRNA species, also develop 
a spontaneous, lethal autoimmune disease virtually indistinguish-
able from that seen in Scurfy mice (7), demonstrating that miRNAs 
are critical for establishment of Treg-mediated peripheral toler-
ance. However, the set of miRNAs responsible for this functional 
deficiency has yet to be fully defined.
MicroRNA-142 (miR-142) is one of a handful of hematopoietic- 
specific miRNAs (16) and exists as 2 mature isoforms — miR-142-
3p and miR-142-5p, generated by ribonuclease processing of the 
sense and antisense strands of the intact double-stranded miR-142 
duplex. Of the 2 mature species, miR-142-5p is the predominant 
form expressed in thymically derived Tregs (17). Importantly, the 
mature sequence of miR-142 is evolutionarily conserved between 
murine and human species, making it an attractive target for 
translation from murine studies to human clinical use (18). miR-
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super-enhancers has previously 
allowed for the definition of key 
lineage-specific genes critical 
for controlling T cell identity 
(24–26). Following our analysis, 
the only miRNA gene associat-
ed with a Foxp3 super-enhancer 
in Tregs was Mir142, located 
approximately 2 kb upstream of 
the fifth ranked Foxp3-associ-
ated super-enhancer (Figure 1A 
and Table 1). FOXP3 bound this 
locus both in thymically derived 
Tregs analyzed directly ex vivo 
(tTreg) and in Tregs induced in 
vitro from naive CD4+ T cells 
activated in the presence of 
TGF-β and IL-2 (iTreg) (Figure 
1A). The Mir142 locus was also 
associated with high levels of 
histone H3 lysine-4 tri-methyl-
ation (H3K4me3) in both tTreg 
and iTreg and was transcription-
ally active (Figure 1A). These 
data suggest that miR-142 is 
important for Treg function.
Generation and validation of 
TregΔ142 mice. We next set out to determine whether miR-142 was 
important for Treg biology or immune tolerance. To do this, we 
undertook a conditional gene-knockout strategy and generated a 
Treg-specific miR-142–deficient mouse (FoxP3YFP–Cre × Mir142fl/fl; 
TregΔ142, where YFP indicates yellow fluorescent protein). The 
FoxP3YFP–Cre model allowed for deletion of a target gene in Tregs 
only, as previously described (27). Furthermore, because the Fox-
P3YFP–Cre allele is X-linked, this allowed assessment of the effects 
of mosaic disruption of miR-142 in female mice that are hetero-
zygous for FoxP3YFP–Cre (FoxP3YFP–Cre/WT × Mir142fl/fl). For clarity, 
TregΔ142 refers only to male FoxP3 YFP–Cre × Mir142fl/fl and homozy-
gous female FoxP3YFP–Cre × Mir142fl/fl mice.
FoxP3 staining of YFP+ cells from these mice demonstrated 
that more than 95% of FACS-sorted YFP+ cells were FoxP3+ (Fig-
ure 1B), confirming the validity of YFP as a means of identifying 
Tregs in this model. Quantitative reverse-transcription PCR (qRT-
PCR) conducted on total RNA isolated from YFP+ cells sorted 
from TregΔ142 mice confirmed a complete absence of miR-142 tran-
scripts, which were otherwise readily detectable in control cells, 
validating Cre-mediated deletion of the Mir142 locus in Foxp3- 
expressing cells (Figure 1C). Non-Treg T cell populations from 
these mice demonstrated miR-142 expression levels comparable to 
those of controls, demonstrating a lack of detectable background 
Cre-recombinase activity in this model (Figure 1C). These mice 
also did not demonstrate any of the lymphopenic features previ-
ously reported in Mir142–/– animals (28), retaining a full spectrum 
of other T cell lineages with equivalent levels of miR-142 in naive 
CD4+ T cells from WT (FoxP3YFP–Cre × Mir-142+/+), TregΔ142, and WT 
YFP+ mice (Figure 1, D and E), further confirming Treg-specific 
deletion of miR-142 in TregΔ142 mice.
142-5p expression is downregulated in CD4+ T cells from patients 
with the multisystem autoimmune disease systemic lupus erythe-
matosus (SLE) compared with healthy controls and overexpressed 
in an animal model of multiple sclerosis, suggesting that miR-142 
plays a role in autoimmune disease (19, 20).
In this study, we show that miR-142-5p directly targets phos-
phodiesterase-3b (Pde3b) mRNA, limiting PDE3B protein levels 
in Tregs. PDE3B hydrolyzes its substrates cAMP and 3′-5′-cyclic 
guanine monophosphate (cGMP) to AMP and GMP, respectively, 
thus accelerating intracellular cAMP and cGMP turnover (21). The 
suppressive function of Tregs is critically dependent on the intra-
cellular concentration of cAMP (22), with Tregs maintaining high 
levels of intracellular cAMP and Teffs requiring low cAMP levels 
to undergo activation (23). Collectively, our findings reveal a crit-
ical role for miR-142-5p in the regulation of intracellular cAMP 
concentration via modulation of Pde3b expression in Tregs and 
therefore place miR-142-5p in the center of the molecular circuitry 
that regulates Treg suppressive function.
Results
miR-142 is associated with a super-enhancer occupied by FOXP3 
in Tregs. We first sought to identify miRNA genes related to the 
commitment to, or function of, the CD4+ Treg lineage. To address 
this, we utilized ChIP coupled with next-generation sequencing 
(ChIP-Seq) to identify whether any miRNA genes were associated 
with super-enhancers occupied by FOXP3, the lineage-determin-
ing transcription factor (LDTF) of Tregs. Foxp3 super-enhancers 
are genomic regions that exhibit particularly high occupancy 
of LDTF and transcriptional coactivators and tend to be asso-
ciated with cell type–specific genes (24). The identification of 
Table 1. miR-142 is the only microRNA associated with the highest ranked FOXP3-bound super-
enhancers in mouse Tregs
Enhancer rank Chr Start Stop Closest gene Distance to closest TSS
1 chr8 129371463 129391915 Tomm20 77906
2 chr4 32337202 32345516 Bach2 –158893
3 chr14 54846952 54853334 Dad1 20270
4 chr6 108486925 108503880 Itpr1 Within gene
5 chr11 87558486 87568424 Mir142 –1941
6 chr6 129179073 129184784 2310001H17Rik Within gene
7 chr15 61996321 62001568 Pvt1 Within gene
8 chr19 53495621 53499465 Smndc1 –30557
9 chr12 102121473 102133871 Gpr68 Within gene
10 chr10 13702612 13713611 Hivep2 Within gene
11 chr16 49790990 49799225 Cd47 –56541
12 chr17 84729938 84732636 Thada Within gene
13 chr17 29530547 29532572 Fgd2 32688
14 chr15 72980095 72992645 Eif2c2 Within gene
15 chr17 52301754 52302516 Gm20098 279702
16 chr13 43870595 43873683 Cd83 –6792
17 chr10 95833510 95837468 Btg1 –242166
18 chr12 74694414 74706077 Prkch Within gene
19 chr11 34495132 34495979 Dock2 Within gene
20 chr19 53515926 53517976 5830416P10Rik Within gene
Bold text shows Mir142. TSS, transcription start site; Chr, chromosome.
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of peripheral immune tolerance, we examined the T cell com-
partment of the immune system of these animals in more detail. 
Immunological phenotyping of TregΔ142 mice at 5 to 6 weeks of 
age revealed normal numbers of Tregs in the thymus (Figure 2A), 
TregΔ142 mice demonstrate a defect in Treg suppressive function 
despite apparently normal Treg lineage development. To establish the 
impact of Treg-specific miR-142 deletion on the development and 
biological function of TregΔ142 Tregs, as well as the maintenance 
Figure 1. TregΔ142 mouse: validation data. (A) ChIP-Seq binding profiles (reads/million, input subtracted) for FOXP3 and H3K4me3 and mRNA-Seq (reads/
million) around miR142 in Tregs. Genes and super-enhancers are shown below and a scale bar above. Tregs are defined as CD4+CD25+FOXP3+. (B) Flow 
cytometric gating on YFP (sorted and fixed live CD4+ cells) and concomitant/subsequent FOXP3 staining. (C) miR-142-5p expression in naive CD4+ T cells 
and YFP+ Tregs in WT and TregΔ142 by RT-qPCR. n ≥ 3. *P < 0.05; **P < 0.001, 2-tailed Student’s t test. (D) Total CD3 counts in spleen (n = 4 per group) and 
peripheral lymph node. n = 7 per group. Nonsignificant, 2-tailed Student’s t test. (E) Total CD4 counts in spleen and peripheral lymph node in absence of 
disease (<10 weeks; n = 5; nonsignificant, 2-tailed Student’s t test) and presence of disease (>10 weeks; n = 3; nonsignificant, 2-tailed Student’s t test).
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side the low expression of CD127 (IL-7Rα) typical of Tregs (Figure 
2C). Intracytoplasmic cytokine staining of CD4+ cells isolated 
directly ex vivo from TregΔ142 mice demonstrated an increased pro-
portion of cells expressing cytokines, including IFN-γ, IL-2, IL-4, 
spleen, and peripheral lymph nodes (Figure 2B). The expression of 
FOXP3 was unaffected in the absence of miR-142 (Figure 2C), and 
the canonical Treg markers ICOS, GITR, and CTLA-4 were equiv-
alently expressed between peripheral TregΔ142 and WT Tregs along-
Figure 2. MiR-142–deficient Tregs develop normally, but fail to suppress Teff responses in vitro. (A) Number and proportion (%) of FOXP3+ (CD4+YFP+) 
cells at successive stages of thymus development (n = 4 per group). (B) Number of FOXP3+ cells in spleen (left) and peripheral lymph node (pLN) (right) 
samples (n = 8). (C) Flow cytometry histograms of peripheral Tregs (CD4+CD25+FOXP3+) stained for surface and intracellular Treg markers (n ≥ 4 per group). 
(D) Flow cytometry and cytokine secretion profiles of CD3+CD4+ and CD3+CD8+ T cells. **P < 0.01, 2-tailed Student’s t test. n ≥ 4 per group. (E) Flow cytome-
try and intracytoplasmic cytokine capture data for CD25 surface expression and IL-2 production in TregΔ142 (CD4+YFP+) versus WT Tregs (CD4+CD25+FOXP3+). 
**P < 0.01, 2-tailed Student’s t test. n = 6 per group. (F) Coculture suppression assays; P value represents comparison of WT Tregs, WT Teffs, and TregΔ142 
WT Teffs (data combined from 3 independent experiments). CTV, CellTrace Violet. *P < 0.05, 2-tailed Student’s t test. n > 3 per group.
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(Figure 4E). This observation implied a relative homeostatic 
defect of miR-142–deficient Tregs in the presence of miR-142–
sufficient Tregs in vivo. This conclusion was further substanti-
ated by the finding that female FoxP3YFP–Cre/WT × Mir142fl/fl mice 
remained healthy up to at least 24 months of age, with no weight 
loss, overt disease, or histological evidence of inflammation (Fig-
ure 4, F and C). Similarly, cytokine secretion profiles of CD4+ 
T cells from these mice were comparable to those of littermate 
control WT mice, demonstrating that the predominance of miR-
142–sufficient Tregs maintained immunological tolerance (Fig-
ure 4G). However, in comparison with YFPneg Tregs, YFP+ Tregs 
from FoxP3YFP–Cre/WT × Mir142fl/fl animals exhibited reduced in 
vitro suppressive activity of Teffs (Figure 4B), similar to the levels 
observed in YFP+ Tregs from TregΔ142 mice. From this we infer that 
the miR-142–deficient Treg suppressive defect is cell intrinsic and 
directly attributable to cell-specific loss of miR-142 expression.
Pde3b is a direct target of miR-142-5p in Tregs. To understand the 
mechanism underlying the phenotype associated with Treg-specif-
ic miR-142 deletion, we next attempted to identify genes directly 
regulated by miR-142 in Tregs. Argonaut 2 (AGO2) binds mature 
miRNAs as part of miRISC, which directs translational inhibition 
and degradation of target mRNAs (2). Therefore, to begin our 
target identification screen, we first identified mRNAs bound by 
AGO2 at predicted miR-142 target sites in activated CD4+ cells, 
utilizing publicly available AGO2 high-throughput sequencing 
of RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP) data (29). We further reasoned that Treg miR-142 target 
genes should be upregulated in Tregs in the absence of miR-142 
and downregulated in WT Tregs versus Teffs. Thus, we required 
that candidate miR-142 target genes were upregulated (>2-fold, 
P < 0.05) in TregΔ142 Tregs versus WT Tregs and downregulated 
(>2-fold, P < 0.05) in WT Tregs versus Teffs (30). As miR-142-3p is 
minimally expressed in Tregs compared with miR-142-45p (18), we 
reasoned that miR-142-5p was likely to be the main active mature 
miR-142 species in Tregs. Application of these stringent criteria 
identified 3 candidate miR-142-5p target genes: Pde3b, Epas1, and 
Igf2bp3 (Figure 5A). To confirm that these genes were directly tar-
geted by miR-142 as predicted, we utilized a flow cytometry–based 
reporter assay. The inclusion of the Pde3b 3′ UTR region containing 
the predicted binding site in the reporter construct led to robust 
repression of reporter gene expression in the presence of miR-142 
(Figure 5B). This repression was completely reversed by mutation 
of the seed sequence at the predicted target site (Supplemental 
Figure 1B; supplemental material available online with this article; 
https://doi.org/10.1172/JCI124725DS1). In contrast, the repression 
was modest for the regions containing the predicted binding sites 
in the Epas1 and Igf2bp3 3′ UTRs and was not relieved by mutating 
the seed sequences in either case (Supplemental Figure 2, A and B). 
Therefore, we concluded that Pde3b is a direct target of miR-142-5p 
and that the predicted miR-142-5p–binding sites in the 3′ UTRs of 
Epas1 and Igf2bp3 are not truly functional.
PDE3B regulates the intracellular concentration of cAMP and 
is critical for Treg function (23, 25). We therefore sought to deter-
mine whether the critical requirement of miR-142 for Treg suppres-
sive function was associated with the direct repression of Pde3b by 
miR-142-5p. Supporting the hypothesis that miR-142-5p directly 
targets Pde3b in Tregs, qPCR confirmed significant overexpres-
IL-5, and IL-17, versus WT CD4+ T cells, representing unchecked 
peripheral Teff responses. In addition, 60% of CD8+ T cells from 
TregΔ142 mice produced IFN-γ, versus less than 20% of CD8+ T 
cells from WT mice (Figure 2D). Tregs from TregΔ142 mice also 
demonstrated upregulated CD25 expression and IL-2 production 
(Figure 2E), which may reflect a compensatory increase in Treg 
activation in the absence of miR-142. Tregs purified from TregΔ142 
mice at 5 to 6 weeks of age completely failed to suppress Teff pro-
liferation in an in vitro coculture suppression assay (Figure 2F), 
revealing a defect of Treg suppressive function despite apparently 
normal Treg lineage development and increased Treg activation. 
These data indicate that, following commitment to the Treg lin-
eage, miR-142 is not essential for the maintenance of the periph-
eral Treg pool. However, its expression is critical for maintenance 
of the Treg activation state and optimal suppression of cytokine 
production by Teffs under steady-state conditions.
The TregΔ142 Treg suppressive defect is cell intrinsic and leads to 
development of lethal multisystem inflammatory disease. Given the 
functional suppressive defect displayed by TregΔ142 Tregs, we 
anticipated that these animals may develop a Scurfy-like pheno-
type and, indeed, this was the case. Starting from 6 to 8 weeks 
of age, mice homozygous for the Mir142fl/fl allele, and possess-
ing either 1 (male) or 2 (female) FoxP3YFP–Cre alleles, developed a 
severe multisystem inflammatory disease, characterized by runt-
ing, weight loss, and death by 20 weeks (Figure 3, A and B). An 
early macroscopic feature of the disease phenotype was extensive 
dermatitis (Figure 3C). Postmortem examination was notable for 
marked lymphadenopathy and splenomegaly (Figure 3C). Histo-
logical examination of the liver, lungs, and skin of affected mice 
also revealed profound lymphohistiocytic infiltration (Figure 3D), 
very similar to that seen in the Scurfy mouse, as well as in mice 
lacking Treg-specific Dicer and Drosha (7, 12–15). In comparison 
with FoxP3YFP–Cre mice homozygous for the floxed miR-142 allele, 
male and female FoxP3YFP–Cre mice heterozygous for the floxed 
allele (Mir142fl/+) did not become terminally ill and remained visu-
ally healthy up to at least 12 months of age, with no weight loss 
or overt signs of disease (Figure 4A). Furthermore, Tregs from 
these mice retained normal suppressive activity in vitro (Figure 
4B). However, histological examination of the liver, lungs, and 
skin revealed some mild/patchy inflammation (Figure 4C) accom-
panied by modest splenomegaly (Figure 4D). This indicated that, 
while for the most part, mice haplodeficient for miR-142 expres-
sion in Tregs were able to maintain Treg suppressive activity, full 
peripheral tolerance requires normal homozygous expression of 
miR-142, highlighting that the precise miR-142 gene dosage is crit-
ical for endowing full suppressive function.
Since the FoxP3YFP–Cre allele is X linked, only 1 of the 2 
FoxP3YFP–Cre alleles is transcriptionally active in any given Treg 
from a female mouse heterozygous for FoxP3YFP–Cre expression 
(FoxP3YFP–Cre/WT). Due to this random X inactivation, approxi-
mately 50% of Tregs in female FoxP3YFP–Cre/WT mice should be 
predicted to express YFP (denoting FOXP3-Cre activity). Howev-
er, while close to 50% of the total Treg pool from FoxP3YFP–Cre/WT 
× Mir142+/+ mice were found to be YFP+, in female FoxP3YFP–Cre/WT 
animals possessing the floxed allele (FoxP3YFP–Cre/WT × Mir142fl/fl), 
YFP+ cells (i.e., those in which the Mir142 locus had been delet-
ed) were found to represent less than 10% of the total Treg pool 
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sion of Pde3b in TregΔ142 Tregs compared with controls observed by 
RNA-Seq (Figure 5C). However, Pde3b transcript levels in non-Treg 
T cell populations from TregΔ142 and WT mice were not significant-
ly different from one another (Supplemental Figure 3A), further 
validating the specificity of deletion of miR-142 in TregΔ142 Tregs. 
In agreement with previous reports, we found that PDE3B protein 
was not detectable in WT resting Tregs (Supplemental Figure 3B) 
(23). However, PDE3B protein was clearly present in TregΔ142 Tregs, 
as detected by Western blot (Figure 5D), congruent with findings of 
elevated Pde3b levels by qPCR. Consistent with increased PDE3B 
protein, intracellular cAMP levels in TregΔ142 Treg lysate were lower 
compared with those in WT Treg control lysate (Figure 5E), indi-
cating that, not only was there more PDE3B protein present in 
TregΔ142 Tregs, but that the enzyme was also active. Importantly, 
the miR-142-5p target site in the Pde3b 3′ UTR is highly conserved 
among mammals (Table 2), supporting the likely translation of 
these findings in mice to human biology. Combined, these results 
show that Pde3b transcript levels are directly regulated by miR-142-
5p in Tregs, leading to optimal Treg suppressive capacity through 
the maintenance of intracellular cAMP.
Disruption of PDE3B activity through pharmacological inhibi-
tion or genetic ablation restores TregΔ142 Treg–suppressive function and 
prevents lethal autoimmune disease. If the suppressive capacity of 
Tregs from TregΔ142 mice was impaired due to elevated expression 
of Pde3b in the absence of miR-142, inhibition of PDE3B would be 
predicted to reverse this effect. Cilostamide is a competitive inhib-
itor of PDE3A and PDE3B, but of the 2 isoforms, only PDE3B is 
present in T cells (22, 23). We found that pretreatment of Tregs 
from 5- to 6-week-old WT and TregΔ142 mice with cilostamide 
(10 μM) prior to coculture with untreated Teffs in the absence of 
Figure 3. Treg-specific deficiency of miR-142 causes a multisystem lethal autoimmune syndrome due to a failure of peripheral tolerance. (A) Weight 
charts demonstrating weight loss from 7 weeks of age in TregΔ142 males and females. ***P < 0.001, 2-tailed Student’s t test. n > 10 per group. WT and 
TregΔ142 data are also shown in Figure 4A. (B) Survival of TregΔ142 and WT littermate control mice. P < 0.001, 2-tailed Student’s t test. Data combined from 2 
independent experiments. n > 10. (C) Scurfy-type phenotype seen in TregΔ142 mice (16-week-old female mouse shown); gross splenomegaly and lymphade-
nopathy seen in TregΔ142 mice. (D) H&E staining of formalin-fixed, paraffin-embedded sections from ear skin, liver, and lung. Original magnification, ×20 
(skin); ×10 (lung, liver). WT and TregΔ142 skin, lung, and liver histology are also shown in Figure 6E.
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cilostamide restored the suppressive function of TregΔ142 Tregs 
(Figure 5F). No rescue of suppressive function was observed when 
Teffs were pretreated with cilostamide (not shown). Tregs from 
Pde3b-deficient mice demonstrate marginal augmentation of ex 
vivo suppressive capacity when compared with WT Tregs, similar 
to that seen in WT Tregs treated with cilostamide in vitro (Figure 
5, F and G). These data suggest that PDE3B may be expressed 
following TCR ligation in WT Tregs or that perhaps a low level of 
Figure 4. The cell-intrinsic Treg suppressive defect is directly attributable to cell-specific loss of miR-142 expression. (A) Weight charts of WT, TregΔ142, and 
Foxp3YFP–Cre × Mir142fl/+ mice (male and female; n > 9). WT and TregΔ142 data are also shown in Figure 3A. (B) Coculture suppression assays (data combined from 
3 independent experiments). P values represent comparison between WT, TregΔ142, Foxp3YFP–Cre/WT × Mir142fl/fl, and Foxp3YFP–Cre × Mir142fl/+. **P < 0.01; ***P < 
0.001, 1-way ANOVA. n > 4 per group. No significant difference noted between WT and Foxp3YFP–Cre × Mir142fl/+. (C) H&E staining of formalin-fixed, paraffin- 
embedded sections from ear skin, liver, and lung from FoxP3YFP–Cre/WT × Mir142fl/fl and Foxp3YFP–Cre × Mir142fl/+ mice. Original magnification, ×10. (D) Comparison 
of spleen weights and cell counts. *P < 0.05; **P < 0.01, 1-way ANOVA. n > 6. (E) YFP+ Tregs as a percentage of the total Treg pool (CD4+CD25+FoxP3+) from WT, 
TregΔ142, Foxp3YFP–Cre/WT × Mir142fl/fl (female), and Foxp3YFP–Cre × Mir142fl/+ (male and female) mice. n = 4 per group. ***P < 0.001, 1-way ANOVA. (F) Weights of WT, 
TregΔ142, and Foxp3YFP–Cre/WT × Mir142fl/fl (female). n > 6 per group. One-way ANOVA. (G) Cytokine secretion profiles of CD3+CD4+ and CD3+CD8+ T cells from WT, 
TregΔ142, Foxp3YFP–Cre/WT × Mir142fl/fl (female), and Foxp3YFP–Cre × Mir142fl/+ mice (male and female). n ≥ 3. **P < 0.01; ***P < 0.001, 1-way ANOVA.
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defect in Treg function in the absence of miR-142 is independent 
of any observed homeostatic defect and is rescued by Treg-selec-
tive PDE3B inhibition.
We next sought to determine the relevance of this pathway in 
vivo. Remarkably, treatment of TregΔ142 mice with cilostamide from 
8 weeks of age prevented lethal autoimmune disease (Figure 6A), 
which was correlated with fully restored suppressive activity of 
transient PDE3B expression may exist, consistent with previous 
reports (23). Importantly, while we observed some reduction of 
Treg viability in the absence of miR-142 during in vitro culture, 
mirroring the in vivo loss of competitive fitness in the presence of 
WT Tregs, the recovery of suppressive function following pharma-
cological inhibition of PDE3B was completely independent of this 
defect (Supplemental Figure 4). Thus, our data indicate that the 
Figure 5. Identification of candidate miR-142 target genes in Tregs. (A) Intersection of genes harboring miR-142-5p–binding sites in their 3′ UTRs, as 
predicted by DIANA microT algorithm and by AGO2 HITS-CLIP in activated CD4+ T cells (29) (blue), with genes downregulated (≥2-fold, P < 0.05) in Tregs 
versus Teffs (30) (green) and genes upregulated in miR-142–deficient versus WT Tregs (≥2-fold, P < 0.05) (yellow). (B) Direct targeting of Pde3b mRNA 
3′ UTR by miR-142. Expression of an NGFR reporter gene that has either the WT or mutated (Mut) Pde3b 3′ UTR miR-142-5p–binding site inserted in the 
presence of control or miR-142 expression vector in HEK293T cells. Data are representative of 2 independent experiments. Bars indicate mean and SD.  
n = 8. ***P < 0.001, Student’s t test. (C) Pde3b expression in TregΔ142, Pde3b–/–, and WT Tregs by RT-qPCR. n = 6. ***P < 0.001, 2-tailed Student’s t test. 
Data from 2 independent experiments. (D) PDE3B expression in WT and TregΔ142 Tregs by Western blot (relative density). n ≥ 3. **P < 0.01, 2-tailed Stu-
dent’s t test. Lanes were run on the same gel but were noncontiguous. (E) cAMP ELISA data from Treg cell lysates. n = 4. **P < 0.001, 2-tailed Student’s 
t test. (F) Coculture suppression assay data comparing Treg suppressive function following in vitro cilostamide treatment of Tregs from WT and TregΔ142 
mice. P value signifies comparison between TregΔ142 + cilostamide and TregΔ142 + control. No significant difference between TregΔ142 + cilostamide and WT 
samples. **P < 0.01, 1-way ANOVA. n ≥ 9 per group, combined from 3 independent experiments. (G) Coculture suppression assay data comparing Treg 
suppressive function in WT and Pde3b–/– mice. **P < 0.01, 1-way ANOVA. n ≥ 6 per group. Combined from 2 independent experiments.
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Treg lineage development in our study. However, iTreg devel-
opment has been shown to be positively regulated by miRNAs, 
including miR-15b/16 (32), miR-99a (33), miR-126 (34), and miR-
150, which target and suppress key components of the PI3K/AKT/
MTOR signaling pathway, favoring Treg induction over Teff gen-
eration (35). Likewise, both iTreg and tTreg development are aug-
mented by suppression of cytokine signaling 1 (SOCS1) through 
miR-155 (36). In contrast, other miRNAs, such as miR-17 (37) and 
miR-100 (38), can play inhibitory roles in Treg development via 
suppression of core components of the TGF-β–signaling pathway, 
including TGFβRII and SMAD2/3, or through direct suppression 
or destabilization of Foxp3 mRNA, as has been shown for miR-10a 
(39), miR-15a/16 (40), miR-24 (41), miR-31 (42), miR-125a (43), 
miR-146a (44), and miR-210 (41). We revealed that miR-142-5p 
exerts its critical function in Tregs via facilitation of Treg suppres-
sion of Teffs. At the mechanistic level, this is achieved via main-
tenance of high Treg intracellular cAMP concentration, which is 
essential for subsequent transfer of cAMP to Teffs, suppressing 
their activation (21). In addition to transfer of cAMP, Tregs also 
suppress Teffs through CTLA4, limiting Teff-positive costim-
ulatory signaling through CD28 interactions with CD80/86 in 
antigen-presenting cells. CTLA4 is reported to be targeted by 
both miR-15a/16 (40) and miR-145 (41) in Tregs; however, these 
interactions limit CTLA4 expression and reduce Treg suppressive 
function. Therefore, to our knowledge, this is the first report of an 
miRNA playing a direct, cell-intrinsic positive role in augmenting 
Treg suppressive activity.
Interestingly, while our study clearly demonstrates the criti-
cal requirement of miR-142-5p for maintenance of high intracel-
lular concentration of cAMP in Tregs, miR-142-3p has previously 
been reported to restrict cAMP generation in CD4+ T cells through 
targeted suppression of adenylyl cyclase 9 (AC9) (45). Adenylyl 
cyclases are critically required for cAMP generation, and in their 
report, Huang et al. showed that Teffs maintain high levels of miR-
142-3p in order to restrict AC9 expression, thus limiting endog-
enous cAMP production, which would otherwise inhibit their 
cellular activation (45). However, the authors reported that miR-
142-3p expression is minimized in Tregs in order to support AC9 
expression, facilitating cAMP generation so that Tregs may carry 
out suppression of Teffs. This is in line with other reports detailing 
miR-142-5p as the predominant miR-142 isoform found in Tregs 
(17). Our findings together with these data support a model where-
by differential expression of miR-142 isoforms maintains Treg 
cAMP intracellular concentration. The synthesis of cAMP (low 
miR-142-3p, AC9 increased) as well as the inhibition of its hydro-
lysis to AMP (high miR-142-5p, PDE3B inhibited) may therefore 
represent parallel components of the same molecular goal.
Previously, it has been proposed that FOXP3 maintains the 
lineage stability and homeostasis of Tregs, in part by binding to 
and repressing Pde3b transcription directly, in order to maintain 
high levels of intracellular cAMP (23, 46). However, our data clear-
ly demonstrate that in the absence of miR-142-5p, FOXP3-medi-
ated repression of Pde3b is not sufficient to prevent significant 
upregulation and activity of PDE3B, leading to reduced intracellu-
lar cAMP and the breakdown of peripheral tolerance and lethality. 
Therefore, FOXP3 and miR-142-5p work in concert to maintain 
Pde3b repression, consistent with the established role of miRNAs 
miR-142–deficient Tregs (Figure 6B). To further validate that the 
defect observed in miR-142–deficient Tregs was a direct function of 
increased PDE3B levels, we generated a Pde3b-deficient, Treg-spe-
cific miR-142–deficient mouse (Pde3b–/– × FoxP3YFP–Cre × Mir142fl/fl; 
Pde3b–/– × TregΔ142). We found that these mice (in addition to litter-
mates heterozygous for Pde3b germline deletion) remained healthy 
up to more than 20 weeks of age, with no weight loss, dermatitis, 
or overt disease, and exhibited restored ex vivo Treg suppressive 
function (Figure 6, C and D). Histological examination of the liver, 
lung, and skin showed evidence of only mild, patchy inflammatory 
infiltrate (Figure 6E). To exclude the possibility that this was due 
to impaired immunity in Pde3b-deficient mice, we examined their 
T cell effector function. Pde3b–/– mice had normal T cell numbers 
and effector function when compared with WT Teffs, as previously 
reported (23) (data not shown).
We therefore conclude that miR-142-5p represses Pde3b 
expression in Tregs and that this is essential for Treg suppressive 
function. In the absence of this critical molecular pathway, the 
mechanisms governing peripheral immune tolerance are compro-
mised, resulting in a systemic lethal autoimmune syndrome.
Discussion
The restriction of self-reactive peripheral Teff responses by Tregs 
is a core tenet of the mechanisms underlying peripheral tolerance, 
preventing development of autoimmunity. In the work presented 
here, we have demonstrated that miR-142 plays a critical, cell- 
autonomous role in facilitation of this Treg suppressive activity 
and, by virtue of this, successful orchestration of peripheral toler-
ance. By applying stringent target identification criteria and by val-
idating these targets experimentally, the phosphodiesterase Pde3b 
was revealed to be a direct target of the miR-142 isoform miR-142-
5p in Tregs. These data support the conclusion that, under WT con-
ditions, direct repression of Pde3b by miR-142-5p is a key determi-
nant of Treg function and peripheral immune tolerance.
The work presented in this study contributes to the under-
standing of the role of miRNAs in Treg biology. Previously, it has 
been shown that Tregs display a distinct miRNA expression pro-
file when compared with conventional CD4+ Teffs (31), suggest-
ing a role for specific miRNAs in the different functions of these 
cell types. Treg-specific miR-142 deletion did not appear to affect 
Table 2. Conservation of miR-142-5p target sequences across 
species in the Pde3b 3′ UTR
Pde3b 3′ UTR 1550
Bos taurus (cow) 5′-UUUAAUGAAUCACUAAGCUUUAUU-3′
Sus scrofa (pig) 5′-UUUAAUGAAUUACUAAGCUUUAUU-3′
Felis catus (cat) 5′-UUUAAUGAAUCACCGAGCUUUAUU-3′
Rattus norvegicus (rat) 5′-UUUAAUGAAUCACUACACUUUAUU-3′
Pan troglodytes (chimp) 5′-UUUAAUGAAUCACUAAGCUUUAUU-3′
Homo sapiens (human) 5′-UUUAAUGAAUCACUAAGCUUUAUU-3′
Mus musculus (mouse) 5′-UUUAAUGAAUCACUACACUUUAUU-3′
     || ||  |  ||   ||||||
miR-142-5p 3′-UCAUCAC-GAAAGA--UGAAAUAC-5′
Conserved bases are shown in bold text.
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ly tractable route for augmenting protective immune responses. 
Suppression of miR-142 expression in CD4+ T cells from patients 
suffering from autoimmune diseases such as SLE (19) predicts that 
PDE3B expression and activity may be enhanced in these cells and 
that this may underlie disease etiology. Modulation of this path-
way, either through PDE3B inhibition or via exogenous manipu-
lation of miR-142-5p expression levels or treatment with miRNA 
mimics, may therefore represent viable treatment options in the 
future. A number of PDE3 inhibitors are already widely used as 
in reinforcing transcriptional programs and conferring robustness 
to biological processes (47).
The worldwide surge in the incidence and prevalence of 
autoimmune disease over the last 30 years (including in young-
er people) is associated with a marked socioeconomic burden 
and has generated a global multibillion-dollar treatment market 
(48). Our findings represent a step forward in the understanding 
of the mechanisms governing peripheral immune tolerance, and 
conceivably, modulation of this pathway may provide a clinical-
Figure 6. Pharmacological inhibition of PDE3B or genetic deletion of Pde3b reverses the lethality and phenotype of the autoimmune syndrome induced 
by Treg-specific loss of miR-142. (A) Weight (left) and survival (right) of TregΔ142 and WT littermate control mice after 8 weeks of treatment with 6.4 mg/
kg intraperitoneal cilostamide or control (n ≥ 3 for WT mice and n ≥ 6 for TregΔ142 mice). Loss of more than 15% of body weight was the predefined mortality 
endpoint. (B) Coculture Treg suppression assay after 4 weeks of cilostamide treatment. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA. Data combined 
from 3 independent experiments. (C) Weight (left) and survival (right) of Pde3b–/– × TregΔ142, TregΔ142, Pde3b+/– × TregΔ142, and WT mice. n ≥ 5 (Pde3b–/– × 
TregΔ142); n ≥ 3 (Pde3b+/– × TregΔ142); n ≥ 7 (TregΔ142); and n ≥ 5 (WT mice). (D) Coculture Treg suppression assay comparing germline deletion of Pde3b 
(Pde3b–/– × TregΔ142) with TregΔ142 and WT littermate control mice. P values signify comparison between Pde3b–/– × TregΔ142 and TregΔ142. *P < 0.05; **P < 0.01, 
1-way ANOVA. Data combined from 2 independent experiments. n ≥ 6. (E) H&E staining of formalin-fixed, paraffin-embedded sections from ear skin, liver, 
and lung (left) with histological scoring as described in Methods (right). Original magnification, ×20 (ear skin); ×10 (liver and lung). *P < 0.05, Student’s t 
test. n = 5 (Pde3b–/– × TregΔ142, TregΔ142 and WT); n = 3 (Pde3b+/– × TregΔ142). WT and TregΔ142 skin, lung, and liver histology are also shown in Figure 3D.
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published (63). Chimeric offspring were bred with C57BL/6 mice to 
generate heterozygous lines, then bred with FoxP3YFP–Cre × Mir142fl/fl 
and FoxP3YFP–Cre × Mir142+/+ mice to generate appropriate littermate 
controls to utilize in all experiments. The mice were housed under 
specific pathogen–free conditions.
Flow cytometry and intracellular cytokine staining. Single-cell sus-
pensions were prepared from spleen and peripheral lymph nodes by 
tissue disruption and filtration. Following red cell lysis of splenocyte 
suspensions, an aliquot of 5 × 106 splenocytes was stimulated with 
PMA at 1 ng/ml (MilliporeSigma) and ionomycin at 1 μg/ml (Milli-
poreSigma) for 4 hours at 37°C, 5% CO2, with the addition of mon-
ensin at 2 μM concentration (MilliporeSigma) for the last 2 hours. 
Stimulated and unstimulated samples were then Fc blocked and sur-
face stained with fluorochrome-conjugated anti-mouse antibodies to 
LIVE/DEAD (Life Technologies) and combinations of CD45, CD3, 
CD4, CD8, CD25, CD44, CD62L, ICOS, GITR, CXCR3, and CD127 
(eBioscience). A proportion of cells, including those stimulated with 
PMA and ionomycin, were fixed and permeabilized using a mouse 
Intracellular Staining Kit (eBioscience) per the protocol, and intracel-
lular stains were then applied with fluorochrome-labeled anti-mouse 
antibodies to FoxP3, T-bet, CTLA-4, IFN-γ, and IL-17 (eBioscience). 
Appropriate single-stain controls were utilized for all fluorochromes. 
Cells were acquired on a Fortessa machine (BD Biosciences) and ana-
lyzed using FlowJo software (TreeStar).
For thymus flow cytometric analyses, thymocytes were harvest-
ed from 5- to 6-week-old mice, Fc blocked, and surface stained with 
fluorochrome-conjugated anti-mouse antibodies reporting LIVE/
DEAD (Life Technologies). Half the cells were stained with a gener-
al panel consisting of anti-mouse antibodies to CD24, CD25, CD5, 
TCR-β, CD4, and CD8 (eBioscience), and the other half were stained 
with a double-negative panel consisting of anti-mouse antibodies to 
CD44, and CD25, and primary biotinylated antibodies to CD3, CD4, 
CD8, CD19, TCRγδ, CD11b, CD11c, Ly6G, NK1.1, and Ter119, with a 
subsequent secondary, fluorochrome-conjugated streptavidin step. 
All cells were fixed and permeabilized (as before), stained for Foxp3, 
and acquired and analyzed as before. For cells stained with the dou-
ble-negative panel, dead cells and streptavidin-positive cells were 
excluded and the remaining cells were gated into successive dou-
ble-negative populations by CD44 and CD25 (DN1 CD44+CD25–, 
DN2 CD44+CD25+, DN3 CD44–CD25+, DN4 CD44–CD25–). Full 
details for the antibodies used are listed in Supplemental Table 1.
In vitro suppression assay. CD4+ T cells were isolated from pooled 
peripheral lymph nodes and spleens of 5- to 6-week-old mice using 
CD4 microbeads (Miltenyi Biotec). Cells were labeled with fluoro-
chrome-conjugated anti-mouse antibodies to CD4, CD62L, CD44 
and CD25 (eBioscience) and sorted using a BD FACSAria II flow 
cytometric cell sorter (BD Biosciences) to more than 95% purity for 
YFP+CD4+ cells (Tregs) and naive (CD25–, CD62L+, CD44–) CD4+ T 
cells (Teffs). An aliquot of the sorted Treg population was stained with 
LIVE/DEAD and anti-CD25 antibodies, fixed, and permeabilized, 
then stained for FoxP3 and acquired on a flow cytometer (as before) 
to confirm purity. The Teffs were labeled with 10 μM CellTrace Vio-
let (Life Technologies) according to the manufacturer’s instructions, 
washed, and then cultured in a 96-well U-bottom plate alone or with 
Tregs at ratios ranging from (Teff/Treg) 1:1 to 32:1, in triplicate, in the 
presence of anti-CD3 and anti-CD28 Dynabeads (Life Technologies), 
at a bead/cell ratio of 2:1, and RPMI 1640 cell culture medium (Gibco, 
therapeutic agents, for example, cilostazol in the treatment of 
intermittent claudication (49, 50). With over 100 clinical trials 
registered on ClinicalTrials.gov for cilostazol alone, the pharma-
codynamic, tolerability, and safety profiles of these drugs have 
been under careful evaluation for a number of years. However, 
none of these trials is focused on assessing the potential thera-
peutic applications of PDE3 inhibitors in the treatment of auto-
immune disease. In light of our findings, there is now a prece-
dent for further investigation to establish whether modulation of 
PDE3B activity in Tregs may help to reestablish mechanisms of 
tolerance in patients suffering from autoimmune disease.
In addition to the potential relevance of our findings for treat-
ment of autoimmune disease, identification of miR-142-5p as 
a critical metabolic regulator of Treg suppressive function may 
also have direct relevance to cancer immunotherapy, particularly 
when used for solid tumors. Tregs are enriched in cancer patients, 
particularly within and surrounding the tumor (51, 52). Further-
more, a large number of Tregs within tumors is frequently associ-
ated with poor clinical outcome for patients (53–56). The reasons 
for this are incompletely understood, but appear related to a tumor 
microenvironment rich in TGF-β (57), IL-10 (58), and adenosine 
(59), which promote Treg development, survival, and activity, 
resulting in enhanced suppression of tumor-infiltrating Teffs. 
Alongside other tactics employed by tumor cells, such as elevat-
ed expression of PD-L1, which promotes further suppression of 
antitumor Teff responses through inhibitory interactions with 
PD-1 expressed by activated Teffs (60), tumor-resident Tregs act 
to abolish antitumor T cell immunity through enhanced peripher-
al tolerance to or “immunological ignorance” of the tumor itself. 
Previously, tumor cell–specific miR-142-5p expression has been 
shown to promote tumor immune evasion through inhibition of 
phosphatase tensin homolog (PTEN), leading to downstream 
upregulation of PD-L1, restricting CD4+ T cell antitumor immu-
nity (61), or inducing cancer stem cell–like properties. This in turn 
leads to enhanced growth and reduced apoptosis (62). However, 
the role of miR-142-5p specifically in human tumor-resident Tregs 
has yet to be addressed.
In summary, our results reveal that a critical function of 
miR-142-5p in Tregs is to facilitate Teff suppression via repres-
sion of PDE3B, leading to reduction of intracellular cAMP turn-
over. Therefore, this mechanism may prove a future avenue for 
Treg-targeted immunotherapies for autoimmune disease and 
solid tumors as well as for augmenting the response to pathogens.
Methods
Animals. Mir142fl/fl mice were generated by homologous recombina-
tion in 129S mouse embryonic stem cells using a targeted vector con-
taining both FRT and loxP sites flanking the Mir142 locus as well as a 
neomycin resistance cassette to enable constitutive and conditional 
miR-142–deficient generation (performed by Genoway). Chime-
ric offspring were bred with C57BL/6J-Flp deleter mice to generate 
conditional lines, which were subsequently fully backcrossed onto 
a C57BL/6 background. Appropriate control mice were utilized in 
all experiments, with age- and sex-matched littermate FoxP3YFP–Cre 
× Mir142+/+ mice (WT) as controls for the FoxP3YFP–Cre × Mir142fl/fl 
(TregΔ142) line. Pde3b–/– mice were a gift from Vincent Manganiello 
(NIH, Bethesda, Maryland, USA) and were generated as previously 
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time PCR instrument (Applied Biosystems). Results were expressed 
relative to U6 or β-actin using the 2−ΔCt method.
FoxP3 ChIP-Seq in mouse Tregs. CD4+ T cells from spleens and 
lymph nodes of 4- to 10-week old C57BL/6 mice were purified by 
CD4-positive selection (Miltenyi Biotec) followed by sorting of naive 
CD4+CD25–CD62LhiCD44lo cells using a FACSAria II (BD Bioscienc-
es). Cells were activated by plate-bound anti-CD3 and anti-CD28 
(both 10 μg/ml; clones 145-2C11 and 37.51, respectively; Bio X Cell). 
Tregs were generated by culturing in recombinant human TGF-β1 (33 
ng/ml) and IL-2 (20 ng/ml, R&D Systems) for 7 days. Th1 cells were 
polarized as previously described (26). ChIP for FoxP3 was performed 
as described (26) using a mix of 2 antibodies: Santa Cruz sc-31738 and 
eBioscience FJK-16. Libraries were constructed and sequenced as pre-
viously described (26).
Previously published sequencing data. The following data sets were 
downloaded from the NCBI’s Gene Expression Omnibus database: 
mouse nTreg FoxP3 ChIP-Seq: GEO GSM999179 and GSM999181 
(input) (66); mouse iTreg H3K4me3 ChIP-Seq: GEO GSM362005 
(67); mouse nTreg H3K4me3 ChIP-Seq: GEO GSM362007 (67); and 
mouse iTregmRNA-Seq: GEO GSM1480828 (25).
ChIP-Seq and RNA-Seq data analysis. Reads were filtered to 
remove adapters using fastq-mcf and for quality using seqkt. ChIP-Seq 
reads were aligned to mm9 with Bowtie2 (default settings). FOXP3 
ChIP-Seq data were filtered for satellites and blacklisted regions (26) 
and super-enhancers identified with the ROSE algorithm using the 
default settings (68). RNA-Seq data were aligned with TopHat to mm9 
(default settings) and converted to bigwig format as described (26). All 
ChIP-Seq data were deposited in the GEO database (GSE72279).
Microarrays and target prediction algorithms. Total RNA was 
extracted using TRIsure (Bioline) as before. cDNA was prepared using 
the Ovation Pico WTA Kit (NuGEN Technologies) and hybridized 
to Affymetrix Mouse Gene ST 2.0 microarrays by the King’s College 
London Genomics Centre facility. All cell populations used for the 
microarray analysis were generated in duplicate and individually pro-
cessed. Raw data were processed with the robust multi-array average 
RMA algorithm (69) for probe-level normalization, and differential 
expression was estimated using the limma package in Bioconductor 
(70). Data from the arrays (GEO GSE122881) were compared with 2 
public domain data sets: DIANA microT-predicted miR-142-5p target 
sites within CLIP-defined Ago2-binding sites in activated CD4+ T cells 
(29) and genes downregulated 2-fold or less at P = 0.05 in Tregs ver-
sus Teffs (30). Published microarray data were downloaded from GEO 
(GSE14350) and analyzed as described above.
Development of flow cytometry–based miRNA-target reporter gene 
assay. The direct interaction of an miRNA and a putative target is com-
monly confirmed by using a luciferase reporter assay in which the 3′ 
UTR of the gene tested is cloned downstream of a luciferase reporter 
gene. Using such an assay, we found that expression of miR-142 led 
to downregulation of the Renilla firefly reporter activity independent-
ly of the presence of the Pde3b 3′ UTR. These findings are consistent 
with a previous report (71) that identified several miR-142–binding 
sites in the Renilla luciferase cDNA. Therefore, we instead generated 
a new flow cytometry–based reporter system that contains the trun-
cated human low-affinity nerve growth factor receptor (NGFR, also 
called CD271) gene as a readout for miRNA-target interaction (Sup-
plemental Figure 1A). As an internal transfection control, the vector 
expresses the cell-surface marker Thy1.1 (also called CD90.1) under 
Life Technologies) supplemented with 10% fetal calf serum, 50 μM 
2-mercapto-ethanol, 2 μM l-glutamine, pyruvate, HEPES, nonessen-
tial amino acids, and antibiotics at 37°C 5% CO2. All 4 possible com-
binations of Tregs and Teffs from each group were utilized. After 72 
hours in culture, the cells were stained with fluorochrome-conjugated 
anti-mouse antibodies to LIVE/DEAD (Life Technologies), and then 
proliferation of the Teffs was assessed by flow cytometry based on 
CellTrace Violet dilution (excluding YFP+ and dead cells). The num-
bers of nonproliferating cells (events in the first peak) and precursors 
of proliferating cells were calculated using standard formulae. Per-
centage suppression (S) of proliferation was calculated using the fol-
lowing formula: S = 100 − ([c/d] × 100), where c is the percentage of 
proliferating precursors in the presence of Tregs and d is the percent-
age of proliferating precursors in the absence of Tregs.
Histology of tissue samples. Mice were sacrificed between 6 and 20 
weeks of age with age- and sex-matched WT controls. Samples of liver, 
lung, and ear skin were fixed in 10% neutral buffered formalin for 48 
hours before paraffin embedding, sectioning, and staining with H&E 
(MilliporeSigma). Sections were scored blinded using histological 
scoring systems previously published for dermal inflammation (64) 
and lung/liver injury (65). Microscopy was performed with an Olym-
pus BX51 microscope.
Measurement of intracellular cAMP. Tregs were isolated by flow 
cytometric cell sorting as above and washed 3 times with cold PBS. 
They were then lysed and the lysates used to measure cAMP using a 
Parameter cAMP Assay Kit according to the manufacturer’s instruc-
tions (R&D Systems).
In vitro cilostamide treatment. Tregs were isolated by flow cyto-
metric cell sorting as above. They were then cultured in the presence 
of 10 μM cilostamide (Sigma-Aldrich) or equivalent PBS/DMSO con-
trol for 48 hours before being washed twice, counted, and used in an 
in vitro coculture suppression assay, as above. Pretreatment of Tregs 
with cilostamide prior to coculture, as opposed to treatment during the 
assay, was employed to prevent inadvertent treatment of Teffs as well 
as Tregs, excluding an effect of cilostamide on non-Treg populations 
in the suppression coculture assay.
In vivo cilostamide treatment. Littermate TregΔ142 and WT mice 
were treated from 8 weeks of age with alternate day intraperitoneal 
injections of either 6.4 mg/kg cilostamide (MilliporeSigma) in PBS 
10% DMSO or a control solution of PBS 10% DMSO. The mice were 
weighed every other day and monitored for signs of disease. A pro-
portion of mice were sacrificed after 4 weeks of treatment, and Tregs 
were isolated directly ex vivo for use in an in vitro coculture suppres-
sion assay (as before). A proportion of mice were kept alive for as long 
as possible (either until they lost more than 15% of their body weight 
and had to be euthanized or until the end of the experiment).
RNA extraction and RT-qPCR. Total RNA was extracted using TRI-
sure (Bioline) according to the manufacturer’s instructions. MiR-142-
5p RT-qPCR and cDNA reverse transcription were performed accord-
ing to the manufacturer’s instructions using TaqMan assays (Applied 
Biosystems), with U6 small nuclear RNA or miR-191-5p endogenous 
controls. For Pde3b RT-qPCR, cDNA was prepared according to the 
manufacturer’s instructions using the Revertaid cDNA Kit (Ther-
mo Fisher) and qPCR was performed using the Maxima Probe/ROX 
qPCR Master Mix (Thermo Fisher), with a specific primer/probe set 
for Pde3b (Life Technologies) and β-actin as an endogenous control. 
All qPCR reactions were analyzed using an ABI Prism 7900HT real-
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endogenous control. The blots were developed using enhanced che-
miluminescence (Thermo Scientific/Pearce), images acquired using 
image lab 6.0.1 software, and the density of bands analyzed using Fiji 
ImageJ software (72).
Statistics. All between-group differences in flow cytometric, 
RT-PCR, microarray, and ELISA parameters were analyzed using 
1-way ANOVA with Tukey’s test. Two-tailed Student’s t tests were 
used to analyze the flow cytometry–based reporter assay system 
results. Statistical analyses were carried out using GraphPad Prism 6 
(GraphPad Software). P < 0.05 was considered statistically significant. 
Data are represented as mean ± SEM.
Study approval. All experiments were performed according to 
King’s College London and national guidelines, under a UK Home 
Office Project License (PPL:70/7869 to September 2018; P9720273E 
from September 2018).
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control of a separate promoter. Both expression cassettes were sepa-
rated by a synthetic poly(A) signal and transcriptional pause element 
to stop read-through of the NGFR transcript.
The portion of NGFR encoding the intracellular domain was PCR 
amplified and inserted into BglII + EcoRI sites of pcDNA3 (Invitro-
gen). A second expression cassette consisting of the Thy1.1 cell-sur-
face marker under the control of the phosphoglycerate kinase 1 pro-
moter was inserted into NotI + SalI sites of pMY-IRES-EGFP (Cell 
Biolabs) from which the IRES-EGFP element had been removed. To 
avoid interference in expression between the 2 reporter genes, a syn-
thetic poly(A) signal/transcriptional pause region was amplified by 
PCR using pGL4.13 (Promega) as a template, digested with XhoI/
EagI, and inserted upstream of the PGK promoter into XhoI and 
NotI sites. A multiple cloning site consisting of restriction sites for 
EcoRI-NheI-SacII/NotI-XhoI was generated by annealing 2 synthe-
sized oligonucleotides, which were ligated into EcoRI + XhoI sites. 
From this vector, the MCS-poly(A)-PGK-Thy1.1 cassette was excised 
with EcoRI + SalI and inserted into EcoRI + XhoI sites of pcDNA- 
tNGFR, resulting in pcDNA-tNGFR-poly(A)-PGK-Thy1.1 (Supplemen-
tal Figure 1A). A 207 bp fragment of the Pde3b 3′ UTR (base position 
1448 to 1654) containing a predicted miR-142-5p target site was PCR 
amplified from cDNA and inserted into NotI + XhoI sites of pcDNA- 
tNGFR-poly(A)-PGK-Thy1.1. Reporter vectors contained positions 
1–959 of the Igf2bp3 3′ UTR and positions 2253–2258 of the Epas1 3′ 
UTR. A mutated reporter construct was generated through substitu-
tion of 5 bases in the seed sequence (base position 1566 to 1570) by 
overlap PCR (Supplemental Figure 1B). Sequences of primers used are 
listed in Supplemental Table 2.
miRNA-target reporter gene assay. HEK293T cells were plated into 
12-well plates at 7.3 × 104 cells/well, 24 hours before transfection, and 
3.28 ng pcDNA-tNGFR-poly(A)-PGK-Thy1.1 reporter plasmid contain-
ing either the WT or mutated Pde3b 3′ UTR and 1.17 μg pMY-miR-142-
IRES-PAC or pMY-IRES-PAC control plasmid was cotransfected into 
each well using polyethyleneimine (Polysciences) in quadruplicate. 
Reporter expression was determined 48 hours after transfection by 
staining the cells with anti-NGFR-APC and anti-Thy1.1-eFluor450 
(both eBiosciences), followed by staining with CYTOX Blue (Life Tech-
nologies) for LIVE/DEAD cell discrimination. Events were acquired 
with a BD Fortessa. Data are expressed as the ratio between the median 
fluorescence intensity (MFI) values obtained for NGFR and the Thy1.1 
MFI values followed by averaging of the quadruplicate measurements. 
The reporter expression values from samples transfected with the miR-
142 expression vector were normalized to the values of the samples 
transfected with the empty expression vector, which was set to 1.
Western blot. Cells were washed in ice-cold PBS and lysed in RIPA 
buffer (MilliporeSigma) according to the manufacturer’s instructions. 
The protein concentration was quantified using a Pierce BCA Pro-
tein Assay Kit (Thermo Scientific) according to the manufacturer’s 
instructions, and 20 μg protein was used for each sample. The lysed 
samples were then boiled in laemmli buffer and proteins resolved 
using SDS-PAGE (Bio-Rad) before being transferred to a nitrocellu-
lose membrane. Blots were blocked with either 5% milk in Tris-buff-
ered saline, 0.1% Tween-20 (TBST), or 5% BSA in TBS-Tween and 
then probed with rabbit anti-mouse Pde3b antibody (SMCP3B) (cata-
log NBPI-43333, Novus Biologicals). HRP-conjugated goat anti-rabbit 
IgG was used for secondary detection (GE Healthcare) and polyclonal 
β-actin antibody (catalog 4967, Cell Signaling Technology) used as an 
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